

ISSN 1420-3049 http://www.mdpi.org

Studies on the Synthesis and Reactivity of Novel Benzofuran-2-yl-[3-Methyl-3-Phenylcyclobutyl] Methanones and their Antimicrobial Activity

Murat Koca¹, Misir Ahmedzade¹, Alaaddin Çukurovali^{1,*} and Cavit Kazaz²

¹ Firat University, Faculty of Arts and Sciences, Chemistry Department, 23119 Elazig, Turkey ² Ataturk University, Faculty of Arts and Sciences, Chemistry Department, Erzurum, Turkey

*Author to whom the correspondence should be addressed; e-mail: acukurovali@firat.edu.tr

Received: 7 January 2004; in revised form: 10 February 2005 / Accepted: 15 February 2005 / Published: 31 August 2005

Abstract: Preparation in excellent yields of cyclobutyl benzofuran-2-yl- and naphthofuran-2-yl-ketones, the corresponding ketoximes and thiosemicarbazones, ether derivatives of the ketoximes and thiazoles derived from the thiosemicarbazones are described. Two of the synthesized compounds have been tested against eight different microorganisms and found to be active against some of the species studied.

Keywords: Furans, cyclobutane, oxime, thiazole, thiosemicarbazone.


Introduction

Synthetic benzofuran derivatives have received considerable attention owing to their antifungal N-myristoyl transferase inhibitor activity [1] and their activity as potent non-steroidal reversible inhibitors of P450 aromatase [2]. On the other hand, the electron-transfer-catalyzed [2+2] cycloreversion of cyclobutanes has important biological implications in splitting the cyclobutane-type pyrimidine dimers in UV damaged DNA [3, 4], and may have potential applications for photochemical energy storage [5]. The benzofuran ring system itself is a common structural element that appears in a large number of medicinally important compounds [6]. Benzofuran neolignans and nor-neolignans, which are contained in most plants, have attracted much attention in medicinal chemistry for their wide range of various biological activities, including insecticidal, fungicidal, antimicrobial and antioxidant properties [7].

The present investigation was performed for the purpose of synthesizing derivatives of benzo- and napthofuran-2-yl-[3-methyl-3-phenylcyclobutyl]-methanones. These derivatives are oximes, epoxy ether derivatives of the oximes, thiosemicarbazones and thiazoles. This approach seems to be useful in view of the fact that it may combine the physiological action of the two groups with the well-known biological activity of the compounds containing cyclobutane, thiazole and benzofuran groups. As far as we know this is the first report on these substances.

Results and Discussion

The synthetic route followed is shown in Scheme 1. One of the starting compounds, 3-phenyl-3-methyl-1-(2-chloro-1-oxoethyl)cyclobutane, was synthesized according to the general procedure described in [8], starting from acrolein and dry chlorine, and subsequently isobutylene. Benzofuran derivatives were prepared from 2-hydroxy-5-bromobenzaldehyde or 2-hydroxy naphthalaldehyde and 3-phenyl-3-methyl-1-(2-chloro-1-oxoethyl) cyclobutane in different solvents.



The first reaction involves a nucleophilic substitution reaction in acetone between 3-phenyl-3methyl-1-(2-chloro-1-oxoethyl) cyclobutane and the potassium salts of 2-hydroxy-5-bromo benzaldehyde or 2-hydroxynaphthalaldehyde. As a result of: (i) the strong nucleophilicity of the potassium salts of aldehydes, (ii) the absence of steric hindrance by 3-phenyl-3-methyl-1-(2-chloro-1oxoethyl) cyclobutane and (iii) the increased positive charge of the positive center of the carbocation formed by the elimination of chloride from the latter, due to the inductive effect of chlorine atom, the acetone solvent provides a relatively mild temperature conditions for the formation of the expected substances with excellent yields. In Scheme 1, the compounds 1, 3, 5, 7, and 9 have the R substituent, while 2, 4, 6, 8, and 10 include the R_1 one.

The first compound, benzofuran-2-yl-(3-methyl-3-phenylcyclobutyl) methanone (1), is prepared in the presence of potassium carbonate in excellent yield (94%). It was expected that this compound should have two different isomers in the *cis* and *trans* configurations, due to the methyl and phenyl groups on the cyclobutane ring may. In fact, the starting material, 3-phenyl-3-methyl-1-(2-chloro-1oxoethyl) cyclobutane itself is an 85:15 mixture of *cis* and *trans* isomeric structures [8]. Unfortunately, only one isomer was separated, possible a result of the crystallization technique. In the second step, this compound was converted into its corresponding oxime **3** in 4:1 alcohol-water in the presence of pyridine by a well known method. The yield of the reaction was good (74%). As is known, oximes can be found in two different isomeric structures namely, the *syn* and *anti* configurations [10,11]. As expected, compound **3** (and similarly compound **4**) shows two different isomeric structures. As can be seen from its ¹H-NMR spectra, both $-CH_3$ and oxime (N-OH) groups have double peaks. The oxime group has a descreening effect [9], and thus the low-field signals are assigned to the *E*-isomer, while the signals at the high-field are assigned to the *Z*-isomer. Since the ratios of the *E*- and *Z*- isomers in the initial ketoximes and in the alkylation and acylation reaction products does not coincide in most cases, a partial *E*/*Z*-isomerization probably takes place.

Reactions of **3** and **4** with epichlorohydrin, in the presence of KOH, gave oxime ethers **5** and **6**. It is expected that these compounds must also be in different isomeric structures and it has been seen from the ¹H-NMR spectra, that indeed these compounds are isomeric mixtures. Some functional groups of these compounds showed double peaks in the ¹H-NMR spectra. Especially, substance **5** has two singlets at 1.57 and 1.62 ppm for $-CH_3$ and four doublets at 4.12-4.50 ppm range for N-O-CH₂-protons. When doublets are expanded, some additional doublets are shown. These results mean that these compounds have different isomeric structures resulting from *cis* and *trans* isomers on cyclobutane ring and *syn* and *anti* isomers on the oxime or the mixtures of these isomeric structures. Each one of the remaining four compounds **7**, **8**, **9** and **10** has only one isomeric structure.

The ¹³C-NMR resonances and IR data which are given in the Experimental section and the elemental analysis results confirm the identity of the compounds. All the compounds synthesized here are solid substances, stable at room temperature and not affected by atmospheric conditions over at least in two weeks. On the other hand, as these compounds contain cyclobutane, benzofuran, Schiff base, carbazone and thiazole functions in their molecules, they seem to be suitable candidates for further chemical modifications and may be pharmacologically active and useful as ligands in coordination chemistry.

For the biological evaluation of the compounds prepared some representative examples were screened against eight different microorganisms (six bacteria and two yeasts). The test results obtained are listed in Table 1. Antifungal and antibacterial data for ampicillin and nystatin are also included in

this Table for the purpose of comparison. The data show that these compounds generally exhibited moderate toxicity in the high concentrations towards many of the bacterias tested. Unexpectedly both of the substances tested showed no toxicity against all the yeasts. Biological activity studies of the substances on some other different bacterias and yeasts are in progress.

Compound	B. s. LM622	E. a. CCM 2531	E. c. ATCC 25922	L. m. SCOTTA	P. a. DSM 5007	S. a. COWAN I	C. a. FMC 17	S. c. FMC 16
7	9	6	9	9	—	9		
8	8	10	8	10	8	_		
A.50	34		33	46	_	43		
B.50							18	22

Table 1 Antimicrobial effect of the compounds*

* For microbe species see Experimental. Compound concentrations = $500 \mu g/disc$. Including disc diameter (6 mm), A.50: Ampicillin 50 $\mu g/disc$, B.50: Nystatin 50 $\mu g/disc$. The symbol (—) means that the compounds have no activity against the micro organisms.

Experimental

General

Benzene, acrolein, benzaldehyde and amines were purchased from Merck and used as received. Melting points were determined on a Thomas Hoover melting point apparatus and are uncorrected. The IR spectra were measured with Mattson 1000 FT-IR spectrophotometer. The ¹H-NMR spectra were recorded on a Varian-Gemini 200 MHz spectrometer and are reported in ppm (δ) relative to tetramethylsilane (TMS) as the internal standard and ¹³C-NMR (50.34 MHz) is referenced to deuterochloroform (CDCl₃). Elemental analyses were determined on a LECO CHNSO-932 auto elemental analysis apparatus. Analyses (TLC) were performed on precoated 0.2 mm Merck kieselgel 60 F₂₅₄ plates, visualizing with 254 nm UV lamp. Column chromatography was performed using Merck silica gel, 70-230 mesh. Solvents were dried and purified by known conventional methods prior to use. As the preparation for the ten compounds are identical in pairs, we describe below the synthesis of **1**, **3**, **5**, **7** and **9** as representative examples for all the compounds.

General procedure for the synthesis of ketones 1 and 2.

In a two necked 250 mL flask equipped with a reflux condenser, a mixture of 5-bromosalicylaldehyde (4.02 g, 20 mmol), potassium carbonate (2.76 g, 20 mmol) and 3-phenyl-3-methyl-1-(2-chloro-1-oxoethyl) cyclobutane (4.45 g, 20 mmol) in acetone (100 mL) was refluxed for 8 h. The solvent was removed under reduced pressure and the residue was extracted with diethyl ether, the etheral phase dried over anhydrous MgSO₄, filtered and the solvent removed under reduced pressure. Solid substance **1** thus obtained was crystallized from acetone. (5-Bromo-1-benzofuran-2-yl)(3-methyl-3-phenylcyclobutyl)methanone (1). Yield: 6.93 g (94%); m.p.: 134-135 °C (from acetone); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring), 542 (C-Br) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ : 1.64 (s, 3H, CH₃), 2.49 (m, 2H, CH₂), 2.81 (m, 2H, CH₂), 4.08 (q, 1H, >CH-), 7.15-7.83 (m, 9H, aromatics); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 193.74(C=O), 156.19, 154.90, 152.99, 133.04, 130.97, 130.34, 127.68, 126.64, 126.11, 118.93, 115.98, 113.77, 40.88, 38.97, 38.84, 32.54. Anal. Calcd. For C₂₀H₁₇BrO₂: C 65.05, H 4.64. Found: C 65.04, H 4.60.

(*3-Methyl-3-phenylcyclobutyl*)(*naphtho*[2,1-*b*]*furan-2-yl*)*methanone* (**2**). Yield: 1.18 g (74%); m.p.: 148 °C (from ethanol); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ: 1.69 (s, 3H, CH₃), 2.53 (m, 2H, CH₂), 2.88 (m, 2H, CH₂), 4.17 (q, 1H, >CH-), 7.17-8.18 (m, 12H, aromatics); ¹³C-NMR (50.34 MHz; CDCl₃) δ: 193.36 (C=O), 155.97, 153.75, 153.17, 132.53, 131.72, 131.08, 130.32, 130.21, 129.38, 127.62, 127.51, 126.69, 125.37, 124.95, 114.78, 113.73, 40.91, 39.13, 38.66, 32.54. Anal. Calcd. For C₂₀H₁₇BrO₂: C 84.68, H 5.92. Found: C 84.57, H 5.61.

General procedure for the synthesis of ketoximes 3 and 4.

Compound 1 (3.689 g, 10 mmol), hydroxylamine hydrochloride (0.781 g, 12 mmol) and pyridine (5 mL) were dissolved in ethyl alcohol (50 mL). The mixture was refluxed to complete the reaction while monitoring its course by IR. After cooling to room temperature, the mixture was poured into water. The solid 3 thus separated was filtered off, washed with water several times and crystallized from ethanol.

(*Z*)-(*5-Bromo-1-benzofuran-2-yl*)(*3-methyl-3-phenylcyclobutyl*)*methanone oxime* (**3**). Yield: 3.57 g (93%); m.p.: 193 °C (from ethanol); IR (KBr): 3201 (N-OH), 1602 (C=N), 1251 (C-O, on furan ring), 990 (N-O, oxime) [8,9], 544 (C-Br) cm⁻¹. ¹H-NMR (200 MHz; DMSO-d₆) δ : 1.49 and 1.54 (two s, 3H, CH₃), 2.42-2.63 (m, 4H, CH₂), 3.92 (q, 1H, >CH-), 7.10-7.96 (m, 9H, aromatics), 11.75 and 12.03 (two s, 1H, N-OH); ¹³C-NMR (50.34 MHz; DMSO-d₆) δ : 155.17, 154.58, 153.74, 153.23, 149.62, 148.65, 132.08, 131.82, 130.37, 129.94, 127.01, 126.40, 126.24, 126.15, 125.52, 117.27, 117.18, 115.19, 113.70, 106.62, 42.17, 41.60, 40.50, 40.37, 40.29, 40.23, 40.08, 32.10, 31.91. Anal. Calcd. For C₂₀H₁₈BrNO₂: C 62.51, H 4.72, N 3.65. Found: C 62.35, H 4.81, N 3.67.

(*Z*)-(*3-Methyl-3-phenylcyclobutyl*)(*naphtho*[2,1-*b*]*furan-2-yl*)*methanone oxime* (**4**). Yield: 1.81 g (94%); m.p.: 205-208 °C (from ethanol); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring) cm⁻¹, ¹H-NMR (200 MHz; CDCl₃) δ : 1.49 and 1.69 (s, 3H, CH₃), 2.59-2.81(m, 4H, CH₂), 4.06 (q, 1H, >CH-), 7.14-7.99 (m, 12H, aromatics), 11.64 and 11.88 (two s, 1H, N-OH; ¹³C-NMR (50.34 MHz; CDCl₃) δ : 154.09, 153.42, 152.05, 147.86, 132.44, 130.79, 130.27, 130.18, 129.39, 128.72, 127.29, 126.88, 126.73, 126.62, 125.84, 125.47, 124.87, 115.14, 114.24, 41.22, 40.73, 33.30, 32.23; Anal. Calcd. For C₂₄H₂₁NO₂: C 81.10, H 5.96, N 3.94. Found: C 81.00, H 5.96, N 3.77.

General procedure for the synthesis of oxyranyl compounds 5 and 6.

In a two necked 250 mL reaction flask equipped with a reflux condenser and a dropping funnel, **3** (3.83 g, 10 mmol) was dissolved in dry acetone (50 mL). To this solution powdered KOH (1.68 g, 30

mmol) was added portions over a 1 h period. Subsequently, epichlorohydrin (2 mL, 30 mmol) was added in 15 minutes and the solution was refluxed for 8 h. The solvent was removed under reduced pressure and the residue was treated with diethyl ether, the etheral phase dried over anhydrous MgSO₄, filtered and the ether was removed under reduced pressure. Thus obtained solid substance **5** was crystallized from ethanol.

(*Z*)-(5-Bromo-1-benzofuran-2-yl)(3-methyl-3-phenylcyclobutyl)methanone O-(oxiran-2-yl-methyl)oxime (5). Yield: 3.04 g (69%); m.p.: 139-142 °C (from ethanol); IR (KBr): 1594 (C=N), 1253 (C-O, on furan ring), 1053 and 1031 (C-O, epoxide), 979 (N-O, oxime) [8,9], 541 (C-Br) cm⁻¹. ¹H-NMR (200 MHz; CDCl₃) δ : 1.57 and 1.62 (two s, 3H, CH₃), 2.47-2.74 (m, 4H, CH₂), 2.87 (t, *J*=6.9 Hz, 2H, -CH₂-O), 3.33 (m, 1H, >CH-O), 3.90 (q, 1H, >CH-), 4.12-4.50 (four d, 2H, N-O-CH₂-), 7.13-7.77 (m, 9H, aromatics); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 154.21, 154.12, 151.00, 149.54, 132.27, 130.99, 130.16, 127.28, 126.71, 126.14, 118.15, 114.97, 114.86, 77.73, 51.98, 46.79, 41.14, 40.58, 33.26, 32.33. Anal. Calcd. For C₂₃H₂₂BrNO₂: C 65.10, H 5.23, N 3.30. Found: C 65.20, H 4.97, N 3.21.

(*Z*)-(*3-Methyl-3-phenylcyclobutyl*)(*naphtho*[2,1-*b*]*furan-2-yl*)*methanone* O-(oxiran-2-yl-methyl)oxime (**6**). Yield: 0.28 g (67%); m.p.: 205-207 °C (from ethanol); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ : 1.66 (s, 3H, CH₃), 2.53-2.75 (m, 4H, CH₂), 2.86 (t, -CH₂-O), 3.28 (m, 1H, >CH-O), 4.00 (q, 1H, >CH-), 4.21-4.53 (four d, 2H, N-O-CH₂-), 7.17-8.23 (m, 12H, aromatics); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 154.26, 153.41, 151.29, 148.07, 132.43, 130.76, 130.15, 129.33, 128.69, 127.24, 126.85, 126.77, 125.80, 125.53, 114.82, 114.64, 114.21, 77.56, 52.14, 46.92, 41.18, 40.72, 33.34, 32.35.Anal. Calcd. For C₂₇H₂₅NO₂: C 82.00 5, H 6.37, N 3.54. Found: C 82.21, H 6.44, N 3.29.

General procedure for the synthesis of thiosemicarbazones 7 and 8.

A mixture of 1 (0.369 g, 1.0 mmol), thiosemicarbazide (0.091 g, 1.0 mmol) and *p*-toluene sulphonic acid (0.010 g, as catalyst) in absolute ethanol (50 mL) was refluxed. The course of the reaction was monitored by TLC. After the solvent was removed under reduced pressure, the residue was treated with water and solid product 7 thus obtained was recrystallized from methanol.

(Z)-(5-Bromo-1-benzofuran-2-yl)(3-methyl-3-phenylcyclobutyl)methanone thiosemicarbazone (7). Yield: 0.42 g (94%); m.p.: 219 °C (from ethanol); IR (KBr,): 3432-3155 (four sharp peaks, thiosemicarbazide), 1598 (C=N), 1244 (C-O, on furan ring), 1045 (C=S), 547 (C-Br) cm⁻¹. ¹H-NMR (200 MHz; CDCl₃) δ : 1.61 (s, 3H, CH₃), 2.47-2.72 (m, 4H, -CH₂-), 3.70 (q, 1H, >CH-), 6.32 (broad s, 2H, -NH₂), 7.02-7.80 (m, 9H, aromatics), 10.82 (s, 1H, -NH-); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 181.48 (C=S), 155.30, 153.37, 151.87, 141.16, 132.15, 130.39, 130.33, 127.66, 126.71, 126.56, 119.41, 115.52, 111.74, 41.00, 40.82, 34.96, 32.55. Anal. Calcd. For C₂₁H₂₀BrN₃OS: C 57.02, H 4.56, N 9.50, S 7.25. Found: C 57.35, H 4.67, N 9.80, S 7.44.

(*Z*)-(*3-Methyl-3-phenylcyclobutyl*)(*naphtho*[2,1-*b*]*furan-2-yl*)*methanone thiosemicarbazone* (**8**). Yield: 0.38 g (91%); m.p.: 217 °C (from ethanol); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ: 1.65 (s, 3H, CH₃), 2.53-2.77 (m, 4H, CH₂), 3.84 (q, 1H, >CH-), 6.31

(broad s, 2H, -NH₂), 7.15-8.21 (m, 12H, aromatics), 10.99 (s, 1H, -NH-); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 181.38 (C=S), 154.84, 153.52, 150.36, 141.69, 132.71, 131.12, 130.70, 130.39, 129.48, 129.26, 127.62, 126.61, 126.53, 125.33, 124.22, 114.32, 111.67, 41.13, 40.86, 34.98, 32.63. Anal. Calcd. For C₂₅H₂₃N₃OS: C 72.61, H 5.61, N 10.16, S 7.75. Found: C 72.98, H 5.68, N 10.23, S 7.82.

General procedure for the synthesis of thiazolyl hydrazones 9 and 10.

A mixture of of 7 (0.442, 1.0 mmol) and dichloroacetone (0.127 g, 1.0 mmol) in dry acetone (40 mL) was stirred at room temperature. The course of the reaction was monitored by TLC. After completing the reaction, the solution was then made alkaline with an aqueous solution of NH_3 (5%). The precipitate was filtered off, washed with same NH_3 solution several times, dried in air and crystallized from EtOH and dried and stored in a desiccator over $CaCl_2$.

(Z)-(5-Bromo-1-benzofuran-2-yl)(3-methyl-3-phenylcyclobutyl)methanone[4-(chloromethyl)-1,3thiazol-2-yl]hydrazone (**9**). Yield: 0.29 g (57%); m.p.: 199 °C (from acetone); IR (KBr): 3351 (-NH-), 1598 (C=N), 1258 (C-O, on furan ring), 762 (C-Cl), 542 (C-Br) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ : 1.63 (s, 3H, CH₃), 2.46-2.79 (m, 4H, CH₂), 3.68 (q, 1H, >CH-), 4.54 (s, 2H, -CH₂-Cl), 6.67 (s, 1H, aromatic in thiazole), 6.94-7.77 (m, 9H, aromatics), 10.99 (broad s, 1H, -NH-); ¹³C-NMR (50.34 MHz; CDCl₃) δ : 171.66, 153.51, 151.78, 141.26, 132.39, 130.88, 130.64, 130.14, 128.28, 127.12, 126.17, 126.04, 125.90, 124.78, 114.27, 111.75, 43.41, 41.23, 40.49, 34.88, 32.38; Anal. Calcd. For C₂₄H₂₁ClBrN₃OS: C 55.99, H 4.11, N 8.16, S 6.23. Found: C 56.02, H 4.21, N 8.04, S 6.33.

(Z)-(3-Methyl-3-phenylcyclobutyl)(naphtho[2,1-b]furan-2-yl)methanone[4-(chloromethyl)-1,3-thiazol-2-yl]hydrazone (**10**). Yield: 0.30 g (61%); m.p.: 207 °C (from acetone); IR (KBr): 1674 (C=O), 1255 (C-O, on furan ring) cm⁻¹; ¹H-NMR (200 MHz; CDCl₃) δ : 1.68 (s, 3H, CH₃), 2.52-2.87 (m, 4H, -CH₂-), 3.84 (s, 1H, >CH-), 4.56 (s, 2H, -CH₂-Cl), 6.67 (s, 1H, aromatic in thiazole), 7.14-8.21 (m, 12H, aromatics), 10.85 (broad s, -NH-). ¹³C-NMR (50.34 MHz; CDCl₃) δ : 172.24, 153.72, 151.09, 140.26, 132.66, 131.03, 130.63, 130.26, 129.93, 129.53, 129.05, 127.42, 127.33, 126.80, 126.41, 125.37, 124.51, 114.27, 110.30, 109.90, 43.61, 41.10, 40.59, 34.91, 32.34. Anal. Calcd. For C₂₈H₂₄ClN₃OS: C 69.19, H 4.98, N 8.65, S 6.60. Found: C 69.09, H 4.98, N 8.82, S 6.63.

Preparation of microbial cultures

Microorganisms were provided from the culture collection of the Microbiology Laboratory of the Biological Sciences of Faculty of Science and Arts, Firat University, Turkey. In this work, *Bacillus subtilis* LM622 (B.s.), *Enterobacter aeruginosa* CCM 2531 (E.a.), *Eschericia coli* ATCC 25922 (E.c.), *Listeria monocytogenes* SCOTTA (L.m.), *Pseudomonas aeruginosa* DSM 50071 (P.a.), *Staphilococcus aureus* COWAN I (S.a.) *Candida albicans* FMC 17 (C.a.), and *Saccharomyces cerevisiae* FMC 16 (S.c.) were used to investigate the bacteriological and antifungal activities of selected substances. The bacteria and yeast strains were nourished in nutrient broth (Difco) and in malt extract broth (Difco), and incubated for 24 and 48 h, respectively. In the Disc Diffusion method, sterile Mueller Hinton Agar (Oxoid) for bacteria and Saburoud Dextrose Agar for yeast were separately inoculated with the test microorganisms. The compounds, dissolved in DMSO as 500

 μ g/disc solutions, were placed in wells (6 mm diameter) in the agar media and the plates were incubated at 32 °C for bacteria (18-24 h) and at 25° C for yeast (72 h) [12]. The resulting inhibition zones on the plates were measured in mm after 48 h (Table 1). The control samples only contained DMSO. The data reported in Table 1 represent the average of three experiments.

References

- Masubuchi, M.; Kawasaki, K.; Ebiike, H.; Ikeda, Y.; Tsujii, S.; Sogabe, S.; Fujii, T.; Sakata, K.; Shiratori, Y.; Aoki, Y.; Ohtsuka, T.; Shimma, N. Design and Synthesis of Novel Benzofurans as a New Class of Antifungal Agents Targeting Fungal N-Myristoyltransferase, Part 1. *Bioorg. Med. Chem. Lett.* 2001, 11, 1833-1837.
- Whomsley, R.; Fernandez, E.; Nicholls, P.J.; Smith, H.J.; Lombardi, P.; Pestellini, V. Substituted 1-[(Benzofuran-2-yl)-Phenylmethyl]-Imidazoles as Potent Inhibitors of Aromatase In vitro and in Female Rats In vivo. *J. Steroid Biochem.* 1993, 44, 675-676.
- 3. Sancar, A. Structure and Function of DNA Photolyase. *Biochemistry*, **1994**, *33*, 2-9.
- 4. Helis, P.F.; Hartman, R.F.; Rose, S.D. Photoenzymic Repair of UV-Damaged DNA A Chemists Perspective. *Chem. Soc. Rev.* **1995**, *24*, 289-&.
- 5. Bren, V.A.; Dubonosov, A.D.; Minkiin, V.I.; Chernoivanov, V.A. Norbornadene-Quadricyclane as Efficient Molecular-System of Accumulation of Solar-Energy. *Usp. Khim.* **1991**, *60*, 913-948.
- Yoo, S.E.; Lee, S.H.; Kim, S.K.; Lee, S.H. The Conformation and Activity Relationship of Benzofuran Derivatives as Angiotensin II Receptor Antagonists. *Bioorgan. & Med. Chem.* 1997, 5, 445-459
- 7. Ward, R.S. Lignans, Neolignans and Related Compounds. Nat. Prod. Rep. 1999, 16, 75-96
- 8. Akhmedov, M.A.; Sardarov, I.K.; Akhmedov, I.M.; Kostikov, R.R.; Kisin, A.V.; Babaev, N.M. Formation of Substituted-Cyclobutanes In the Reaction of 2-(2-Methyl-2-propenyl)-3-Chloromethyloxirane with Aromatic-Hydrocarbons. *Zh. Org. Khim.* **1991**, *27*, 1434-1440.
- 9. Abele, E.; Popelis, Y.; Gavars, M.; Gaukman, A.; Shimanska, M.; Lukevich, E. O-Acylation of Furan and Thiophene Ketoximes Under Liquid-Solid Phase-Transfer Catalysis Conditions. *Khim. Geterotsikl.* **1994**, *7*, 886-890.
- Shridhar, D.R.; Sastry, C.V. R.; Chaturvedy, S.C.; Grumurthy, R.; Sing, P.P.; Rao, C.S.; Junnarkar, A.Y. Synthesis and Pharmacology of Some New Oxime Ethers Derived From 2-Acetyl-5-Arylthiophenes. *Indian J. Chem.* 1984, 23, 692-694.
- 11. Sinha, A.K.; Rastogi, S.N.; Patnaik, G.K.; Srimal, R.C. Synthesis of Oxime Ether Derivatives of Beta-Arylpropiophenones and 2-p-Methoxybenzylindan-1-one as Potential Antiinflammatory and Antiulcer Agents. *Indian J. Chem.* **1993**, *32*, 738-745.
- Collins, C.H.; Lyne, P.M.; Granga, J.M. *Microbiological Methods*, 6th Ed.; Butterworths Co. Ltd.: London, **1989**; p. 410

Sample Availability: Available from the authors.

© 2005 MDPI (http://www.mdpi.com). Reproduction is permitted for noncommercial purposes